Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

The results for Lunsumio, also known as mosunetuzumab, and Polivy, also known as polatuzumab vedotin, came as part of a phase 3 study. Roche said it would now submit results to global health ...

Grupo Dia CEO Martín Tolcachir emphasised Dia's commitment to creating sustainable long-term value for its shareholders and ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which ...

Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, announced that it launched “Lunsumio for intravenous infusion 1 mg” and “Lunsumio for intravenous infusion 30 mg” (generic name: mosunetuzumab ...